AXIM Biotechnologies Delivers Net Negative Carbon Footprint With All-Natural Industrial Hemp

Company's Proprietary Industrial Hemp Development, Production, and Delivery Methods Innovate Global Nutraceutical and Pharmaceutical Markets

New York, New York, UNITED STATES

NEW YORK, Oct. 30, 2014 (GLOBE NEWSWIRE) -- AXIM Biotechnologies (OTC:AXIM) proudly announces its strategic focus: bring to market global innovative solutions that set the "green standard" in the industrial hemp industry.

The industrial hemp plant is documented for its inherent capability of producing more than 25,000 finished products. AXIM Biotechnologies' business model harnesses the power of industrial hemp to benefit human health, provide alternative energy and deliver many other innovative applications. The Company develops strategic partnerships and acquisitions, allowing ongoing research and development in functional foods, nutraceuticals, pharmaceuticals, cosmetics, and clean energy.

George Anastassov, CEO of AXIM Biotechnologies says, "I am absolutely delighted to be at the helm of this one-of-a-kind, innovative company, of which the primary agenda is to provide nutrition, fabric, sustainable alternative energy, pharmaceutical and nutraceutical products. All of these will be produced utilizing innovative, proprietary and environmentally cautious technologies."

Innovations in Health

AXIM Biotechnologies is focused upon unique proprietary delivery mechanisms for the introduction of cannabinoids (i.e. CBD, CBG, CBN), finding solutions for conditions for which there is currently no effective treatment.

Leading by Example

AXIM Biotechnologies' global executive team is a group of highly skilled and specialized professionals. Its members are responsible for the Company's strategic initiatives and global operations. Through various committees, they oversee: operations and business performance, strategy and planning, future and current product manufacturing, risk management, research and development, external affairs, and internal governance.

Dr. George E. Anastassov, MD, DDS, MBA - Chief Executive Officer

Dr. Philip A. Van Damme, DMD MD PhD - Chief Medical Officer

Lekhram Changoer, MSc. BSc. - Chief Technology Officer

To arrange for media interviews, contact Andrew Hard, Public Relations Spokesperson, at or call 858-380-5478.

About AXIM Biotechnologies:

AXIM Biotechnologies (OTC:AXIM) is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.


AXIM Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell, and distribute hemp-based products.


Contact Data